SILVER SPRING, Md., July 10, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today continued to take action in the ongoing response to the COVID-19 pandemic:
The FDA issued a statement in conjunction with preparations to resume domestic inspections, guided by a new a risk-assessment system. The White House Guidelines for Opening Up America Again are providing FDA a roadmap for optimizing operations and new work arrangements, and the Centers for Disease Control and Prevention's (CDC) guidance is informing efforts related to workplace exposures to COVID-19 in non-healthcare settings. To arm FDA investigators with the most reliable and accurate information, the FDA developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. The COVID-19 Advisory Rating system (COVID-19 Advisory Level) uses real-time data to qualitatively assess the number of COVID-19 cases in a local area based on state and national data. The Advisory Level data will be made available to state partners who, under contract, conduct inspections of FDA-regulated entities on the agency's behalf.
At this time, the agency is working toward restarting on-site inspections during the week of July 20. However, resuming these inspections will depend on the data about the virus' trajectory in a given state and locality and the rules and guidelines established by those state and local governments.
The agency issued new Emergency Use Authorizations for diagnostic tests developed by:
The University of California-San Francisco's Health Clinical Laboratories-UCSF Clinical Labs at China Basin (for its molecular-based SARS-CoV-2 RNA DETECTR Assay) and
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...
Getech, a world-leading locator of subsurface resources, is pleased to announce it has won a new contract with East Star Resources, a London-listed company focused on copper exploration, to locate porphyry copper...
BlackRock Asset Management Canada Limited ("BlackRock Canada"), an indirect, wholly-owned subsidiary of BlackRock, Inc. , today announced the final April 2024 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on April...
At the recent Global Food Safety Initiative (GFSI) conference in Singapore, conversations highlighted the need for the food industry to adapt swiftly to changes in the risk landscape and incorporate strategies that go beyond compliance to competitive...
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed,...